These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

503 related items for PubMed ID: 11082141

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study.
    Okin PM, Devereux RB, Harris KE, Jern S, Kjeldsen SE, Lindholm LH, Dahlöf B, LIFE Study Investigators.
    Hypertension; 2007 Nov; 50(5):984-90. PubMed ID: 17893425
    [Abstract] [Full Text] [Related]

  • 27. Electrocardiographic characteristics and metabolic risk factors associated with inappropriately high left ventricular mass in patients with electrocardiographic left ventricular hypertrophy: the LIFE Study.
    Palmieri V, Okin PM, de Simone G, Bella JN, Wachtell K, Gerdts E, Boman K, Nieminen MS, Dahlöf B, Devereux RB.
    J Hypertens; 2007 May; 25(5):1079-85. PubMed ID: 17414673
    [Abstract] [Full Text] [Related]

  • 28. Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE).
    Okin PM, Oikarinen L, Viitasalo M, Toivonen L, Kjeldsen SE, Nieminen MS, Edelman JM, Dahlöf B, Devereux RB, LIFE Study Investigators.
    Circulation; 2009 Apr 14; 119(14):1883-91. PubMed ID: 19332468
    [Abstract] [Full Text] [Related]

  • 29. Cornell product in an electrocardiogram is related to reduced LV regional wall motion.
    Ishikawa J, Yamanaka Y, Watanabe S, Toba A, Harada K.
    Hypertens Res; 2019 Apr 14; 42(4):541-548. PubMed ID: 30542082
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Prognostic impact of baseline and serial changes in electrocardiographic left ventricular hypertrophy in resistant hypertension.
    Salles GF, Cardoso CR, Fiszman R, Muxfeldt ES.
    Am Heart J; 2010 May 14; 159(5):833-40. PubMed ID: 20435193
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Losartan versus atenolol-based antihypertensive treatment reduces cardiovascular events especially well in elderly patients: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Ruwald AC, Westergaard B, Sehestedt T, Kjeldsen SE, Lindholm LH, Wachtell K, Devereux RB, Ibsen H, Nieminen MS, Dahlöf B, Olsen MH.
    J Hypertens; 2012 Jun 14; 30(6):1252-9. PubMed ID: 22499288
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Change in diastolic left ventricular filling after one year of antihypertensive treatment: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study.
    Wachtell K, Bella JN, Rokkedal J, Palmieri V, Papademetriou V, Dahlöf B, Aalto T, Gerdts E, Devereux RB.
    Circulation; 2002 Mar 05; 105(9):1071-6. PubMed ID: 11877357
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.